» Articles » PMID: 38558385

Availability of Individual Proteins for Quantitative Analysis in Postmortem Brains Preserved in Two Different Brain Banks

Overview
Specialties Neurology
Pharmacology
Date 2024 Apr 1
PMID 38558385
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Postmortem brain research is necessary for elucidating the pathology of schizophrenia; an increasing number of studies require a combination of suitable tissue samples preserved at multiple brain banks. In this study, we examined whether a comparative study of protein expression levels can be conducted using postmortem brain samples preserved in different facilities.

Methods: We compared the demographic factors of postmortem brain samples preserved in two institutions and measured and compared the expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and glial fibrillary acidic protein (GFAP) in the prefrontal cortex and superior temporal gyrus. GAPDH is generally used as a loading control for western blotting, and GFAP is considered as an astrocyte marker in the brain.

Results: We found significant differences between the two institutions in postmortem interval, age at death, and preservation time. To reduce the effects of these differences on our measurements, the parameters were set as covariates in our analyses of covariance. Subsequently, no differences in GAPDH and GFAP expression were found between institutions.

Conclusions: When studies are conducted using brain samples preserved in different brain banks, differences in demographic factors should be carefully considered and taken into account by statistical methods to minimize their impact as much as possible. Since there was no significant difference in the protein expression levels of GAPDH and GFAP in either region between the two institutions that preserved the postmortem brains, we concluded that it is possible to perform protein quantitative analysis assuming that there is no effect of difference between two institutions.

Citing Articles

Availability of individual proteins for quantitative analysis in postmortem brains preserved in two different brain banks.

Nagaoka A, Hino M, Izumi R, Shishido R, Ishibashi M, Hatano M Neuropsychopharmacol Rep. 2024; 44(2):399-409.

PMID: 38558385 PMC: 11144605. DOI: 10.1002/npr2.12430.

References
1.
Tandon R, Keshavan M, Nasrallah H . Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008; 102(1-3):1-18. DOI: 10.1016/j.schres.2008.04.011. View

2.
Hino M, Kunii Y, Matsumoto J, Wada A, Nagaoka A, Niwa S . Decreased VEGFR2 expression and increased phosphorylated Akt1 in the prefrontal cortex of individuals with schizophrenia. J Psychiatr Res. 2016; 82:100-8. DOI: 10.1016/j.jpsychires.2016.07.018. View

3.
Nagaoka A, Kunii Y, Hino M, Izumi R, Nagashima C, Takeshima A . ALDH4A1 expression levels are elevated in postmortem brains of patients with schizophrenia and are associated with genetic variants in enzymes related to proline metabolism. J Psychiatr Res. 2020; 123:119-127. DOI: 10.1016/j.jpsychires.2020.02.001. View

4.
Dean B, Boer S, Gibbons A, Money T, Scarr E . Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr Opin Psychiatry. 2009; 22(2):154-60. DOI: 10.1097/YCO.0b013e328323d52e. View

5.
Chuang D, Hough C, Senatorov V . Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2005; 45:269-90. DOI: 10.1146/annurev.pharmtox.45.120403.095902. View